Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (34)
Jinge Zhao, Guangxi Sun, Fengnian Zhao, Junru Chen, Sha Zhu, Nanwei Xu, Haoyang Liu, Jiayu Liang, Xu Hu, Xingming Zhang, Yuchao Ni, Jindong Dai, Zhipeng Wang, Pengfei Shen, Zhenhua Liu, Ni Chen, Jiyan Liu & Hao Zeng. (2023) The therapeutic efficacy of radical prostatectomy and external beam radiation therapy in patients with different pathological patterns of prostate cancer. Asian Journal of Surgery 46:10, pages 4178-4185.
Crossref
Crossref
Nikhil P Mankuzhy, Muayad F Almahariq, Hong Ye, Mitual Amin, Brandon Stone & Daniel J Krauss. (2021) Investigation of the Prognostic Significance of Neuroendocrine Differentiation in Gleason Score 7 to 10 Prostate Adenocarcinoma in Patients With Distant Metastasis After Definitive Radiotherapy. American Journal of Clinical Pathology 155:6, pages 879-886.
Crossref
Crossref
Yuki Tenjin, Shinji Kudoh, Sho Kubota, Tatsuya Yamada, Akira Matsuo, Younosuke Sato, Takaya Ichimura, Hirotsugu Kohrogi, Goro Sashida, Takuro Sakagami & Takaaki Ito. (2019) Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology. Laboratory Investigation 99:11, pages 1622-1635.
Crossref
Crossref
Miika Sainio, Tapio Visakorpi, Teemu Tolonen, Joanna Ilvesaro & G. Steven Bova. (2018) Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer. Pathology - Research and Practice 214:6, pages 848-856.
Crossref
Crossref
Javier C. Angulo, Cristina Redondo, Manuel Sánchez-Chapado, Begoña Colás, Santiago Ropero & José I. López. (2016) Survival predictors in patients with prostate adenocarcinoma with hormonal blockade. Pathology - Research and Practice 212:10, pages 899-903.
Crossref
Crossref
Mariarosa Pascale, Cinzia Aversa, Renzo Barbazza, Barbara Marongiu, Salvatore Siracusano, Flavio Stoffel, Sando Sulfaro, Enrico Roggero, Serena Bonin & Giorgio Stanta. (2016) The proliferation marker Ki67, but not neuroendocrine expression, is an independent factor in the prediction of prognosis of primary prostate cancer patients. Radiology and Oncology 50:3, pages 313-320.
Crossref
Crossref
M S Tretiakova, W Wei, H D Boyer, L F Newcomb, S Hawley, H Auman, F Vakar-Lopez, J K McKenney, L Fazli, J Simko, D A Troyer, A Hurtado-Coll, I M ThompsonJrJr, P R Carroll, W J Ellis, M E Gleave, P S Nelson, D W Lin, L D True, Z Feng & J D Brooks. (2016) Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies. Prostate Cancer and Prostatic Diseases 19:3, pages 264-270.
Crossref
Crossref
Kosuke Fujino, Yamato Motooka, Wael A. Hassan, Mohamed O. Ali Abdalla, Yonosuke Sato, Shinji Kudoh, Koki Hasegawa, Kanako Niimori-Kita, Hironori Kobayashi, Ichiro Kubota, Joeji Wakimoto, Makoto Suzuki & Takaaki Ito. (2015) Insulinoma-Associated Protein 1 Is a Crucial Regulator of Neuroendocrine Differentiation in Lung Cancer. The American Journal of Pathology 185:12, pages 3164-3177.
Crossref
Crossref
Cristian I. Surcel, Inge M. van Oort, Prasanna Sooriakumaran, Alberto Briganti, Peter J.L. De Visschere, Jurgen J. Fütterer, Pirus Ghadjar, Hendrik Isbarn, Piet Ost, Roderick C.N. van den Bergh, Ofer Yossepowitch, Gianluca Giannarini & Guillaume Ploussard. (2015) Prognostic effect of neuroendocrine differentiation in prostate cancer: A critical review. Urologic Oncology: Seminars and Original Investigations 33:6, pages 265.e1-265.e7.
Crossref
Crossref
Vincenza Conteduca, Michele Aieta, Dino Amadori & Ugo De Giorgi. (2014) Neuroendocrine differentiation in prostate cancer: Current and emerging therapy strategies. Critical Reviews in Oncology/Hematology 92:1, pages 11-24.
Crossref
Crossref
P Sargos, L Ferretti, M Gross-Goupil, M Orre, F Cornelis, B Henriques de Figueiredo, N Houédé, C Merino, G Roubaud, B Dallaudiére, P Richaud & A Fléchon. (2014) Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review. Prostate Cancer and Prostatic Diseases 17:3, pages 220-226.
Crossref
Crossref
Liuyang Zhao, Na Yu, Tianfang Guo, Yixuan Hou, Zongyue Zeng, Xiaorong Yang, Ping Hu, Xi Tang, Jian Wang & Manran Liu. (2014) Tissue Biomarkers for Prognosis of Prostate Cancer: A Systematic Review and Meta-analysis. Cancer Epidemiology, Biomarkers & Prevention 23:6, pages 1047-1054.
Crossref
Crossref
Daniel J. Krauss, Mitual Amin, Brandon Stone, Hong Ye, Sylvia Hayek, Matthew Cotant, Jason Hafron & Donald S. Brabbins. (2014) Chromogranin a staining as a prognostic variable in newly diagnosed Gleason score 7-10 prostate cancer treated with definitive radiotherapy. The Prostate 74:5, pages 520-527.
Crossref
Crossref
M I Koukourakis, A Giatromanolaki, M Panteliadou, S E Pouliliou, P S Chondrou, S Mavropoulou & E Sivridis. (2014) Lactate dehydrogenase 5 isoenzyme overexpression defines resistance of prostate cancer to radiotherapy. British Journal of Cancer 110:9, pages 2217-2223.
Crossref
Crossref
Hongzi Liang, Leo Studach, Ronald L. Hullinger, Jun Xie & Ourania M. Andrisani. (2014) Down-regulation of RE-1 silencing transcription factor (REST) in advanced prostate cancer by hypoxia-induced miR-106b~25. Experimental Cell Research 320:2, pages 188-199.
Crossref
Crossref
J.M. Mosquera, H. Beltran & M.A. Rubin. 2014. Pathobiology of Human Disease. Pathobiology of Human Disease
2456
2463
.
Laure Marignol, Karla Rivera-Figueroa, Thomas Lynch & Donal Hollywood. (2013) Hypoxia, notch signalling, and prostate cancer. Nature Reviews Urology 10:7, pages 405-413.
Crossref
Crossref
Jun Ishii, Hanako Sato, Masashi Sakaeda, Yukiko Shishido‐Hara, Chie Hiramatsu, Hiroshi Kamma, Hiroaki Shimoyamada, Masachika Fujiwara, Tetsuya Endo, Ichiro Aoki & Takuya Yazawa. (2013)
POU
domain transcription factor
BRN
2 is crucial for expression of
ASCL
1,
ND
1 and neuroendocrine marker molecules and cell growth in small cell lung cancer
. Pathology International 63:3, pages 158-168.
Crossref
Crossref
Tamara Sequeiros, Marta García, Melania Montes, Mireia Oliván, Marina Rigau, Eva Colás, Inés de Torres, Juan Morote, Jaume Reventós & Andreas Doll. (2013) Molecular Markers for Prostate Cancer in Formalin-Fixed Paraffin-Embedded Tissues. BioMed Research International 2013, pages 1-15.
Crossref
Crossref
Naveen Kachroo & Vincent J. Gnanapragasam. (2012) The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review. Journal of Cancer Research and Clinical Oncology 139:1, pages 1-24.
Crossref
Crossref
Diederick Duijvesz & Guido Jenster. 2013. Prostate Cancer: A Comprehensive Perspective. Prostate Cancer: A Comprehensive Perspective
423
444
.
Himisha Beltran, Juan Miguel Mosquera & Mark A. Rubin. 2013. Prostate Cancer: A Comprehensive Perspective. Prostate Cancer: A Comprehensive Perspective
277
282
.
David Ian Quinn & Gregory P. Swanson. 2013. Biomarkers in Oncology. Biomarkers in Oncology
189
247
.
MIKLÓS TARJÁN, ANNA LENNGREN, DAN HELLBERG & TIBOR TOT. (2012) Immunohistochemical verification of ductal differentiation in prostate cancer. APMIS 120:6, pages 510-518.
Crossref
Crossref
Levent Sagnak, Hikmet Topaloglu, Ugur Ozok & Hamit Ersoy. (2011) Prognostic Significance of Neuroendocrine Differentiation in Prostate Adenocarcinoma. Clinical Genitourinary Cancer 9:2, pages 73-80.
Crossref
Crossref
Daniel J. Krauss, Sylvia Hayek, Mitual Amin, Hong Ye, Larry L. Kestin, Steven Zadora, Frank A. Vicini, Matthew Cotant, Donald S. Brabbins, Michel I. Ghilezan, Gary S. Gustafson & Alvaro A. Martinez. (2011) Prognostic Significance of Neuroendocrine Differentiation in Patients With Gleason Score 8–10 Prostate Cancer Treated With Primary Radiotherapy. International Journal of Radiation Oncology*Biology*Physics 81:3, pages e119-e125.
Crossref
Crossref
Rita Garcia-Parra, David Wood, Rajal B. Shah, Javed Siddiqui, Hero Hussain, Hyunjin Park, Timothy Desmond, Charles Meyer & Morand Piert. (2011) Investigation on tumor hypoxia in resectable primary prostate cancer as demonstrated by 18F-FAZA PET/CT utilizing multimodality fusion techniques. European Journal of Nuclear Medicine and Molecular Imaging 38:10, pages 1816-1823.
Crossref
Crossref
L. Cindolo, M. Cantile, R. Franco, P. Chiodini, G. Schiavo, I. Forte, I. Zlobec, L. Salzano, G. Botti, S. Gidaro, L. Terracciano & C. Cillo. (2011) Parallel determination of NeuroD1, Chromogranin-A, KI67 and androgen receptor expression in surgically treated prostate cancers. International braz j urol 37:1, pages 57-66.
Crossref
Crossref
Ahmed F. Kotb & Ahmed A. Elabbady. (2011) Prognostic Factors for the Development of Biochemical Recurrence after Radical Prostatectomy. Prostate Cancer 2011, pages 1-6.
Crossref
Crossref
Gregory P. Swanson & David Quinn. (2011) Using Molecular Markers to Help Predict Who Will Fail after Radical Prostatectomy. Prostate Cancer 2011, pages 1-15.
Crossref
Crossref
Zhiyong Ma, Norihiko Tsuchiya, Takeshi Yuasa, Mingguo Huang, Takashi Obara, Shintaro Narita, Yohei Horikawa, Hiroshi Tsuruta, Mitsuru Saito, Shigeru Satoh, Osamu Ogawa & Tomonori Habuchi. (2010) Clinical Significance of Polymorphism and Expression of Chromogranin A and Endothelin-1 in Prostate Cancer. Journal of Urology 184:3, pages 1182-1188.
Crossref
Crossref
Alfredo Berruti, Enrico Bollito, Cecilia M. Cracco, Marco Volante, Giovannino Ciccone, Francesco Porpiglia, Mauro Papotti, Roberto Mario Scarpa & Luigi Dogliotti. (2010) The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen‐deprivation therapy. The Prostate 70:7, pages 718-726.
Crossref
Crossref
Morand Piert, Hyunjin Park, Asra Khan, Javed Siddiqui, Hero Hussain, Thomas Chenevert, David Wood, Timothy Johnson, Rajal B. Shah & Charles Meyer. (2009)
Detection of Aggressive Primary Prostate Cancer with
11
C-Choline PET/CT Using Multimodality Fusion Techniques
. Journal of Nuclear Medicine 50:10, pages 1585-1593.
Crossref
Crossref
Sven Gunia, Knut Albrecht, Stefan Koch, Thomas Herrmann, Thorsten Ecke, Volker Loy, Jörg Linke, Michael Siegsmund & Matthias May. (2008) Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability. World Journal of Urology 26:3, pages 243-250.
Crossref
Crossref